The Days of Big Pharma Are Over. What the Era of Big Biotech Means for Investors.

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

Updated June 17, 2022 3:04 pm ET / Original June 17, 2022 3:00 am ET

  • Order Reprints
  • Print Article

Illustration by Mark Pernice

When GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants.

It will mark what is effectively the end of GlaxoSmithKline, diversified pharma conglomerate, and the birth of GSK (ticker: GSK), a rebranded pure-play biopharma.


 » Read More  » Read More

Tags: No tags

Comments are closed.